Clinical Trial Results:
Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year international, multicentre, randomised, double-blind, parallel-group study followed by a 2-year double blind extension.
Summary
|
|
EudraCT number |
2006-001240-30 |
Trial protocol |
BE NL LV DE LT CZ HU SI AT GB SK PT ES |
Global completion date |
10 Nov 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Dec 2016
|
First version publication date |
10 Dec 2016
|
Other versions |
|
Summary report(s) |
Synopsis dated on 03-June-2009 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.